Liensinine alleviates type 2 diabetes mellitus through modulating the pancreatic β cell function and gut microbiota Authors: Yunfei Luo, Xuchang Liu, Yan Zhang, Jiaxin Wu, Yujie Wang, Jing Nie, Ying Ying, Shibo Huang Published: 2025 ABSTRACT BackgroundHerbal compounds are widely recognized for their ​​diverse biological activities, often targeting multiple pathways simultaneously. However, the hypoglycemic effect of liensinine and its underlying mechanisms remain poorly understood. This study aims to clarify how liensinine exerts its blood glucose-lowering effects, with a focus on its impact on pancreatic function and the gut microbiota.MethodsThus, male C57BL/6 mice were randomly assigned to two dietary groups: a standard chow diet or a high-fat diet (HFD) for 4 weeks. Subsequently, type 2 diabetes mellitus (T2DM) was induced in HFD-fed mice using streptozotocin (STZ) injection, and the model was maintained for an additional four weeks. The mice were then further divided into four experimental groups: Control (standard chow), Negative Control (NC, chow-fed mice treated with liensinine at 60 mg/kg), Model (HFD + STZ-induced T2DM mice), and T2DM + Lien (T2DM mice treated with liensinine). The study employed Western blot, Immunofluorescence, and RT-qPCR techniques.ResultsLiensinine alleviated pancreatic injury and hepatic steatosis. It promoted islet cell proliferation, restored normal islet architecture, and balanced alpha- and beta-cell masses. Additionally, liensinine upregulated the expression of METTL3/14 (methyltransferases involved in RNA modification) and pancreatic duodenal homeobox 1 (PDX-1, a key regulator of pancreatic development). Meanwhile, liensinine reduced the abundance of Firmicutes, Lactobacillus, and Actinobacteriota, alongside increased levels of Bacteroides, Akkermansia, and norank_f_Muribaculaceae, concomitant with elevated short chain fatty acids (SCFAs) production in T2DM mice.ConclusionsIn conclusion, these findings indicate that liensinine holds promise as a natural therapeutic agent, exerting beneficial effects on T2DM by ameliorating islet β-cell dysfunction and modulating gut microbiota. Introduction Type 2 diabetes mellitus (T2DM), a multifactorial chronic disorder featuring elevated insulin and glucagon levels, inflicts severe damage to multiple organs, including the pancreas, liver, kidney, and intestine, often accompanied by disruption of the gut microbiota. Restoring microbial balance in the gut has emerged as a promising therapeutic avenue for T2DM management [1]. Moreover, a central pathological feature of diabetes is β-cell dysfunction in the pancreas, leading to inadequate insulin secretion. Therapeutic strategies to preserve β-cell function include inhibiting apoptotic pathways, promoting β-cell proliferation, reducing glucose toxicity, and mitigating oxidative stress [2]. Nowadays, T2DM is rising dramatically, which has become one of the principal inducements of global mortality and disability rates [3]. Hence, identifying drugs capable of reshaping the gut microbiota and restoring β cell function in T2DM remains an intriguing research question. The gut microbiota has emerged as a critical factor in the pathogenesis of metabolic diseases, especially T2DM [4]. Accumulating pre-clinical and clinical data suggest that the imbalance of gut microbiota composition is intricately linked to the initiation, progression, and treatment of T2DM. And modulating gut flora is a promising avenue for T2DM treatment and prognosis. N6-methyladenosine (m6A), as the most prevalent post-transcriptional RNA modification, exhibits significantly reduced levels in patients diagnosed with T2DM [5]. Notably, key m6A regulatory genes - particularly the methyltransferase complex components METTL3 and METTL14 - have been implicated in critical β-cell processes including apoptosis regulation, developmental programming, functional maturation, and inflammatory responses [6–8]. Our preliminary study demonstrated that inducing METTL14 expression could alleviate pancreatic β-cell dysfunction [9]. Currently, the influence of phytochemical natural products on METTL3/14 expression within diabetic pancreatic tissue remains an underexplored area of research. Therefore, developing a novel natural compound to maintain the expression of METTL3/14 in pancreatic tissues is of great clinical significance for the treatment of diabetes. A biologically active alkaloid palmatine can enhance the METTL3/14 expression levels in DSS-treated rats [10]. Similarly, berberine, an isoquinoline alkaloid with established anti-diabetic properties, exerts multifaceted benefits through: (1) modulates intestinal inflammation and alters the microbiota composition of the gut to prevent metabolic dysfunction [11], and (2) improving diabetic complications in T2DM rat models by activating AMPK/mTOR-dependent autophagy while attenuating endoplasmic reticulum stress, thereby ameliorating hepatic steatosis, insulin resistance, and lipid metabolism abnormalities [12]. Among these compounds, liensinine (Lien), an isoquinoline alkaloid derived from lotus plants, is an effective component of lotus plants. Liensinine has shown remarkable metabolic benefits in HFD-fed mice, including mitigation of metabolic syndrome, insulin resistance, and dyslipidemia through dual mechanisms of oxidative stress suppression and anti-inflammatory activity [13]. Liensinine also improves obesity caused by HFD by blocking lysosomal-mediated mitochondrial autophagy [14]. Liensinine and berberine share similarities as isoquinoline alkaloids with multi-target potential, including neuroprotective (e.g., cholinesterase inhibition for liensinine, antioxidant/anti-inflammatory for berberine) and anticancer activities, and both derive from tyrosine via (S)-reticuline in biosynthesis. They differ structurally—liensinine is a dimeric scaffold with a C12 hydroxy group, while berberine is a monomeric tetracyclic structure—and in specific mechanisms: liensinine induces cancer cell apoptosis via PI3K/AKT inhibition and mitochondrial fission regulation, whereas berberine acts through PI3K/Akt/mTOR modulation and ROS generation [15]. While these findings collectively highlight the therapeutic potential of isoquinoline alkaloids in diabetes management, the specific effects of liensinine on pancreatic β-cell function, gut microbiota composition, and METTL3/14 expression in T2DM pathogenesis remain unexplored. This study aims to systematically investigate: (1) liensinine’s impact on pancreatic β-cell function in T2DM mice, (2) its modulatory effects on gut microbiota, and (3) the compound’s influence on METTL3/14 expression - a critical epigenetic regulator of β-cell homeostasis. Methods and materials Experimental mice and protocol All animal procedures were carried out in accordance with the Guide’s Recommendations for the Care and Use of Laboratory Animals, and were approved by the Animal Care and Use Committee of Nanchang University, Jiangxi Medical College (Ethics code: 23W008). We housed 4–5 animals per cage under controlled conditions: 12 h/12 h dark/light cycle, 20 ± 2 ◦C, and unrestricted access to food and water. A total of 26 male C57BL/6 mice (5-week-old) were randomly assigned to dietary interventions: (1) control group (n = 10) maintained on standard chow (Keaoxieli, Cat#1016706476803973120) or (2) high-fat diet group (n = 16) fed a high-fat diet (Hyscbio, D12492, Research Diets) for 4 weeks. Following this period, mice in the high-fat group received intraperitoneal streptozotocin (STZ, 40 mg/kg, Yuanye, S17049) injections once daily for 4 consecutive days after a 6-hour fast to induce type 2 diabetes mellitus (T2DM). One week post-injection, the animal’s fasting blood glucose (FBG) was validated as stable hyperglycemia if it exceeded 11.1mmol/L. The study design progressed with a 4-week intervention phase, during which animals were stratified into four experimental groups: (1) Control (n = 5, standard chow-fed mice), (2) Negative control (n = 5, the core purpose is to verify the safety and specificity of liensinine under physiological conditions, chow-fed mice administered with liensinine), (3) T2DM, (n = 8, HFD + STZ-induced diabetic mice), (4) T2DM + Lien (n = 8, diabetic mice treated with liensinine; during the gavage procedure, a mouse unfortunately expired). Liensinine (Medchemexpress, HY-N0484), administered orally at 60 mg/kg once daily, was utilized in the mouse. 1 mg/mL 5-bromo-2′-deoxyuridine (BrdU, beyotime, ST1056) was provided in drinking water for 7 days before being sacrificed. Glucose tolerance test (GTT) The GTT was carried out following the described method [16]. In brief, during the final week of the animal experiments, the mice were subjected to a 12-hour fast while having unrestricted access to water. After the fasting period, they were given an intraperitoneal injection of glucose at a dose of 2 g/kg. To evaluate glucose tolerance, blood glucose levels were measured at 0, 30, 60, 90, and 120 min post-injection using glucose test strips. The area under the curve (AUC) was then computed to quantify the glucose tolerance capacity. Hepatic and pancreatic tissues dissection and histological analysis Hepatic and pancreatic tissues were formalin-fixed, paraffin-embedded, and sectioned at a thickness of 5 μm for subsequent hematoxylin-eosin (H&E) histological examination. For pancreatic tissue immunofluorescence analysis, sections were microwaved in citrate buffer, cooled, and then blocked with a solution containing 5% BSA in PBS and 0.5% (wt/vol) Triton X-100 for 30 min at room temperature. Primary antibodies were incubated overnight at 4 °C. The following day, the sections were further incubated with the corresponding secondary antibodies for 1 h at room temperature. After the incubation steps, the sections were thoroughly washed to remove any unbound antibodies. Subsequently, 4’, 6-diamidino-2- phenylindole (DAPI, Solarbio, S2110) was used to stain the cell nuclei, which helped in cell localization and visualization. The stained sections were then examined under a confocal microscope (Olympus, Japan) to capture high-resolution images. The primary antibodies used in this study were as follows: a Glucagon Monoclonal antibody (Proteintech, 67286-1-Ig) at a dilution of 1:200 and an Anti-Insulin Recombinant Rabbit Monoclonal Antibody (huabio, ET1601-12) at a dilution of 1:300, as well as an Anti-BrdU Mouse Monoclonal Antibody (huabio, HA601120) at a dilution of 1:200. These primary antibodies were specifically chosen to target key markers in the pancreatic tissue. The secondary antibodies employed were iFluo 594 Conjugated Goat anti-mouse IgG Goat Polyclonal Antibody and iFluo 488 Conjugated Goat anti-rabbit IgG Goat Polyclonal Antibody (HA1126, HA1121), both at a dilution of 1:500. These secondary antibodies were used to detect the primary antibodies and emit fluorescent signals for imaging. Western blot analysis Protein extraction and analysis were performed to evaluate the expression levels of key proteins in pancreatic tissues. Total proteins were extracted from the pancreatic tissues using RIPA lysis buffer (Applygen, C1055) containing 1% protease inhibitor cocktail and 1 mM phenylmethylsulfonyl fluoride (PMSF) to ensure complete protein solubilization and prevent proteolytic degradation. The protein concentration was quantified using the BCA Protein Assay Kit (Applygen, P1511-3) following the manufacturer’s protocol. Extracted proteins were then mixed with 5×SDS-PAGE Protein Sample Loading Buffer (Applygen, B1012-5) and denatured appropriately. For electrophoretic separation, equal amounts of protein samples were loaded onto 10% SDS-polyacrylamide gels. After electrophoresis, the resolved proteins were transferred onto polyvinylidene difluoride (PVDF) membranes. To minimize non-specific binding, the membranes were blocked with 5% non-fat dry milk dissolved in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 60 min at room temperature. The membranes were then incubated overnight at 4 °C with the following primary antibodies: anti-METTL14 (TA378477, OriGene, 1:1000 dilution), anti-METTL3 (TA811770, OriGene, 1:1000 dilution), anti-PDX1 (TA321081, OriGene, 1:1000 dilution), and anti-β-actin (TA811000, OriGene, 1:2000 dilution). β-actin served as the internal loading control. Following thorough washing with TBST to remove unbound primary antibodies, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies specific to the respective primary antibodies for 60 min at room temperature. Protein bands were visualized using enhanced chemiluminescence (ECL) detection reagents and the resulting blots were digitally captured. Quantitative analysis of band intensities was performed using ImageJ software to determine relative protein expression levels, with β-actin serving as the normalization control. RNA isolation and real-time quantitative PCR analysis Total RNA extraction and gene expression analysis were performed to quantify the mRNA levels of target genes in pancreatic tissues. All primers were supplied by Tsingke Biotechnology Co., Ltd. (Beijing, China), based on the PrimerBank (https://pga.mgh.harvard.edu/primerbank/, accessed on 20 October 2023) and are listed in Table 1. For RNA isolation, fresh-frozen pancreatic tissue samples were processed using TRIzol reagent (Invitrogen) following the standard protocol for total RNA extraction. The quality and quantity of extracted RNA were assessed before subsequent analysis. Complementary DNA (cDNA) was synthesized from 1 µg of total RNA using the Sprint qPCR RT Kit (MF949-01, Mei5bio) according to the manufacturer’s instructions. Real-time quantitative PCR (qPCR) was performed using the SYBR qPCR Mix (MF947, Mei5bio) on a StepOnePlus Real-Time PCR System (Applied Biosystems). Each reaction was prepared in a 20 µL volume containing appropriate amounts of cDNA template, gene-specific primers, and SYBR Green master mix. The amplification reactions were conducted in technical triplicate for each biological sample to ensure data reliability. The qPCR thermal cycling conditions consisted of an initial denaturation step at 95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C for 15 s and annealing/extension at 60 °C for 1 min. Fluorescence data were collected during the extension phase of each cycle. Gene expression levels were normalized to β-actin as the internal reference gene. Relative quantification of target gene expression was calculated using the comparative CT method(2− ΔΔ Ct), which compares the CT values of target genes between samples after normalization to the reference gene and calibrator sample. Table 1Primers sequencesGenesPrimer (5’-3’)PDX1-mu-FCCCCAGTTTACAAGCTCGCTPDX1-mu-RCTCGGTTCCATTCGGGAAAGGMETTL14-mu-FCTGAGAGTGCGGATAGCATTGMETTL14-mu-RGAGCAGATGTATCATAGGAAGCCMETTL3-mu-FCTGGGCACTTGGATTTAAGGAAMETTL3-mu-RTGAGAGGTGGTGTAGCAACTTActin -mu-FTATCGCTGCGCTGGTCGActin-mu-RCCCACGATGGAGGGGAATAC Table 1Primers sequencesGenesPrimer (5’-3’)PDX1-mu-FCCCCAGTTTACAAGCTCGCTPDX1-mu-RCTCGGTTCCATTCGGGAAAGGMETTL14-mu-FCTGAGAGTGCGGATAGCATTGMETTL14-mu-RGAGCAGATGTATCATAGGAAGCCMETTL3-mu-FCTGGGCACTTGGATTTAAGGAAMETTL3-mu-RTGAGAGGTGGTGTAGCAACTTActin -mu-FTATCGCTGCGCTGGTCGActin-mu-RCCCACGATGGAGGGGAATAC Primers sequences Gut microbiota analysis and metabolomics profiling Fecal microbial community analysis was performed by extracting total bacterial DNA from mouse colon contents using the TIANamp Stool DNA Kit (DP328). DNA integrity was initially assessed through 2% agarose gel electrophoresis. For microbial profiling, the hypervariable V3-V4 regions of the 16 S rRNA gene were amplified via polymerase chain reaction (PCR) using universal primers. The resulting amplicons were subjected to high-throughput sequencing using the Illumina NovaSeq PE250 platform (Illumina, USA) to generate paired-end sequencing reads. Raw sequencing data underwent comprehensive preprocessing, including Sequence splicing of paired-end reads, Quality control filtration, and Chimera removal to obtain high-quality clean tags. The processed sequencing data were analyzed following standardized microbiome bioinformatics pipelines (https://www.majorbio.com/tools) to determine microbial community composition and diversity metrics. For metabolomic analysis, 100 mg of residual colon contents were processed through a standardized extraction protocol: Initial resuspension in 1 mL methanol via vigorous vortexing (3 min), Sonication treatment (10 min) to enhance metabolite extraction, Centrifugation at 4 °C (14,000 rpm, 5 min) to separate soluble metabolites. The resulting supernatant was collected and diluted 5-fold with methanol to optimize analyte detection. For quantitative analysis: 0.5 mL of the diluted supernatant was combined with 0.5 mL of internal standard solution (5 µg/mL trimethylacetic acid). The final 1 µL aliquot was injected into the Shimadzu QP2010 gas chromatography-mass spectrometry (GC-MS) system. Metabolite identification and quantification were performed using established protocols. Serum biochemical and insulin analysis Serum metabolic parameters and insulin levels were quantitatively assessed using standardized laboratory methodologies. Serum concentrations of key lipid biomarkers were measured using a fully automated clinical chemistry analyzer (Tokyo Hitachi). The following parameters were evaluated: Triglycerides (TG), Total cholesterol (TC), Low-density lipoprotein cholesterol (LDL-C), High-density lipoprotein cholesterol (HDL-C). Serum insulin levels were determined through a quantitative enzyme-linked immunosorbent assay (ELISA) following the manufacturer’s protocol. The analysis employed a commercially available mouse insulin ELISA kit (MM-0579M1, Meimianbio), which utilizes a highly specific antibody-based detection system for accurate insulin quantification. Statistical analysis All quantitative data were processed and analyzed using GraphPad Prism 5 statistical software (San Diego, CA, USA). Data visualization and presentation followed standard scientific reporting conventions, with all experimental results expressed as mean ± standard error of the mean (SEM). For comparative analyses involving multiple experimental groups, one-way analysis of variance (ANOVA) was employed as the primary statistical method to determine significant differences between group means, followed by Tukey’s post hoc test. Statistical significance was defined as a p-value less than 0.05 (p < 0.05). Results Liensinine ameliorated serum lipids, hyperglycemia and insulin sensitivity in T2DM mice In normal mice, oral administration of liensinine at a dosage of 60 mg/kg/day did not induce any significant alterations in fasting blood glucose (FBG) levels when compared to the untreated control group (Fig. 1A). Minimal weight alterations were noted following liensinine administration on normal mice, yet a potential inhibitory effect on high-fat diet-induced weight gain was observed (Fig. 1B). Fig. 1Effect of liensinine on serum lipids, blood glucose and insulin levels in T2DM mice. (A) The fasting blood glucose (FBG) levels in mice. The experimental protocol involved 4 weeks of high-fat diet (HFD) feeding, followed by 1 week of streptozotocin (STZ) injection to induce T2DM, and then 4 weeks of liensinine administration via gavage. (B) Total body weight of the mice. (C, F) The time-course of blood glucose levels during the Glucose tolerance test (GTT) and the corresponding areas under the curve (AUC) of the GTT, respectively. (D, E) The serum TG, TC, LDL-C, HDL-C, and insulin (INS) levels after 4 weeks of administration. All data are expressed as mean ± standard error of the mean (SEM), one-way ANOVA followed by Tukey’s post-hoc test for multi-group comparisons. *p < 0.05 compared with the control group, and #p < 0.05 compared with the T2DM group. n = 5 in the control and negative control (NC) groups, n = 8 in the T2DM group, and n = 7 in the T2DM + liensinine (T2DM + Lien) group Effect of liensinine on serum lipids, blood glucose and insulin levels in T2DM mice. (A) The fasting blood glucose (FBG) levels in mice. The experimental protocol involved 4 weeks of high-fat diet (HFD) feeding, followed by 1 week of streptozotocin (STZ) injection to induce T2DM, and then 4 weeks of liensinine administration via gavage. (B) Total body weight of the mice. (C, F) The time-course of blood glucose levels during the Glucose tolerance test (GTT) and the corresponding areas under the curve (AUC) of the GTT, respectively. (D, E) The serum TG, TC, LDL-C, HDL-C, and insulin (INS) levels after 4 weeks of administration. All data are expressed as mean ± standard error of the mean (SEM), one-way ANOVA followed by Tukey’s post-hoc test for multi-group comparisons. *p < 0.05 compared with the control group, and #p < 0.05 compared with the T2DM group. n = 5 in the control and negative control (NC) groups, n = 8 in the T2DM group, and n = 7 in the T2DM + liensinine (T2DM + Lien) group To comprehensively understand the impact of liensinine on glucose homeostasis and insulin sensitivity in T2DM, we conducted a detailed assessment of FBG and insulin levels in T2DM mice treated with liensinine. At the beginning of liensinine administration, all diabetic mice showed higher FBG levels compared to the normal group (p < 0.05). After 4-week administration, liensinine reduced the FBG levels, whereas the model group maintained high FBG (p < 0.05) (Fig. 1A). Concurrently, liensinine administration reduced serum insulin levels (p < 0.05) (Fig. 1E). In the glucose tolerance test (GTT), a sharp rise of blood glucose level was observed in all groups, peaking at 30 min post-glucose injection, followed by a gradual decline from 30 to 120 min. However, at all measured time points (0, 30, 60, 90, and 120 min), the blood glucose levels in the liensinine-treated group were significantly improved compared to the model group (p < 0.05) (Fig. 2C, F). These findings confirm that liensinine can enhance glucose tolerance in T2DM mice, allowing for more efficient regulation of blood glucose after a glucose challenge. The serum lipid profile of the mice is presented in Fig. 1D. When compared to the T2DM group, liensinine administration resulted in a decrease in the levels of serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) (p < 0.05), while simultaneously increasing the levels of high-density lipoprotein cholesterol (HDL-C) (p < 0.05). These changes in the lipid profile suggest that liensinine can effectively improve the disordered lipid metabolism in T2DM mice. Collectively, these results demonstrate that liensinine has a multi-faceted beneficial effect on T2DM mice. It can ameliorate serum lipid abnormalities, reduce hyperglycemia, and enhance insulin sensitivity. These findings highlight the potential of liensinine as a promising therapeutic agent for the management of T2DM and its associated metabolic complications. Fig. 2Liensinine administration for 4 weeks ameliorates pancreatic islet function and liver pathology in T2DM mice. (A, D) Hematoxylin and eosin (H&E) staining was performed on pancreatic (Scale bar, 20 μm) and liver tissues (Scale bar, 100 μm), with islet area quantification calculated from H&E-stained sections. (B, E, G) Double-immunostaining using specific antibodies, illustrates the distribution of α-cells (glucagon-positive, red) and β-cells (insulin-positive, green) within pancreatic tissues, the nuclei were counterstained with DAPI (blue) for cellular localization, quantitative analysis of these sections enabled calculation of the ratios of β-cell and α-cell areas relative to total islet area (Scale bar, 76.8 μm). (C, F) Pancreatic sections stained for BrdU (red, proliferation marker), insulin (green, β-cell marker), and DAPI (blue, nuclear marker), the percentage of proliferating β-cells was quantified based on co-localization of BrdU and insulin signals (Scale bar, 76.8 μm). All quantitative data are presented as mean ± SEM (n = 5), one-way ANOVA followed by Tukey’s post-hoc test for multi-group comparisons. *p < 0.05 compared to control group and #p < 0.05 compared to T2DM group Liensinine administration for 4 weeks ameliorates pancreatic islet function and liver pathology in T2DM mice. (A, D) Hematoxylin and eosin (H&E) staining was performed on pancreatic (Scale bar, 20 μm) and liver tissues (Scale bar, 100 μm), with islet area quantification calculated from H&E-stained sections. (B, E, G) Double-immunostaining using specific antibodies, illustrates the distribution of α-cells (glucagon-positive, red) and β-cells (insulin-positive, green) within pancreatic tissues, the nuclei were counterstained with DAPI (blue) for cellular localization, quantitative analysis of these sections enabled calculation of the ratios of β-cell and α-cell areas relative to total islet area (Scale bar, 76.8 μm). (C, F) Pancreatic sections stained for BrdU (red, proliferation marker), insulin (green, β-cell marker), and DAPI (blue, nuclear marker), the percentage of proliferating β-cells was quantified based on co-localization of BrdU and insulin signals (Scale bar, 76.8 μm). All quantitative data are presented as mean ± SEM (n = 5), one-way ANOVA followed by Tukey’s post-hoc test for multi-group comparisons. *p < 0.05 compared to control group and #p < 0.05 compared to T2DM group Liensinine modulates the islet and liver morphology, pancreatic islet alpha/beta-cell mass and cell proliferation in T2DM mice To investigate the impact of liensinine on pancreatic and liver tissue damage as well as β-cell function in T2DM mice, histopathological analysis was conducted. Hematoxylin-eosin (H&E) and immunofluorescence staining were employed to visualize tissue structures. These staining techniques revealed that liensinine administration could restore the damaged pancreatic islets in T2DM mice. The areas of islets, insulin-positive β-cells, and glucagon-positive α-cells were quantitatively analyzed. As depicted in Fig. 2A, H&E-stained pancreatic tissue sections from different groups showed distinct patterns. The control group exhibited well-preserved islet structures, with clearly visible pancreatic β-cells. In contrast, the T2DM group, induced by an HFD and STZ, displayed severely atrophied pancreatic islets. However, after liensinine supplementation, the necrosis of islets and damage to pancreatic β-cells were alleviated, and the ratio of the islet area to the pancreatic area was increased (p < 0.05) (Fig. 2D). Additionally, obvious damage of the liver tissue was observed in the diabetic mice, including hepatic steatosis, and extensive intracellular vacuolization. By contrast, liensinine had markedly hepatoprotective effects to ameliorate the vacuolization in the liver. Meanwhile, the ratio of insulin-positive β-cell area to islet area was increased by liensinine administration (Fig. 2B, E). Conversely, the ratio of the glucagon-positive α-cell area to the islet area was decreased by liensinine (p < 0.05) (Fig. 2B, G). These changes in cell area ratios suggest that liensinine can regulate the balance between α- and β-cells in the pancreatic islets. Bromodeoxyuridine (BrdU) staining was used to assess cell proliferation. Compared to the model group, T2DM mice treated with liensinine had approximately six times more insulin and BrdU double-positive cells (0.191 ± 0.3% vs. 1.2606 ± 0.335%, p < 0.05) (Fig. 2C, F). This finding indicates that liensinine can promote the proliferation of insulin-producing β-cells. In summary, these results suggest that liensinine can improve pancreatic islet function by promoting β-cell proliferation, reducing islet and liver damage, and regulating the balance of α- and β-cells in T2DM mice. These effects contribute to the overall improvement of the pancreatic and liver physiological states in the context of T2DM. Liensinine upregulates METTL3/14 expression in pancreatic of T2DM mice To elucidate the molecular mechanisms underlying liensinine’s beneficial effects on pancreatic function in T2DM mice, we conducted targeted molecular analyses focusing on two critical regulators of pancreatic β-cell biology. Specifically, we examined the expression of METTL3 and METTL14, which constitute the core m6A methyltransferase complex [17], and PDX1, a pivotal transcription factor essential for pancreatic β-cell development and maturation [18]. As illustrated in Fig. 3A-C, our quantitative analyses revealed that liensinine treatment significantly upregulated the expression levels of METTL3, METTL14, and PDX1 in the pancreatic tissues of T2DM mice (p < 0.05). This coordinated upregulation suggests a potential regulatory network involving these key molecules. The observed upregulation of METTL3, METTL14, and PDX1 collectively indicates that liensinine may enhance pancreatic function through activation of the METTL3/14-mediated m6A methylation pathway. This pathway appears to play a crucial role in maintaining β-cell identity and function, with PDX1 serving as a downstream effector of m6A-mediated epigenetic regulation [19]. These findings provide compelling evidence that liensinine’s pancreatic protective effects are mediated, at least in part, through enhancement of the METTL3/14-mediated m6A methylation pathway. The concurrent upregulation of both the methyltransferase complex components (METTL3/14) and the β-cell specification factor (PDX1) suggests a coordinated molecular mechanism whereby liensinine promotes proper β-cell function and maintenance in the diabetic state. Fig. 3Liensinine administration for 4 weeks regulates METTL3/14-mediated m6A methylation pathway in the pancreas of T2DM mice. (A, B) The expression of METTL3, METTL14, and PDX1 was analyzed using Western blot. (C)Relative mRNA expression levels of PDX1 and METTL3/14. Data are expressed as mean ± SEM (n = 3), one-way ANOVA followed by Tukey’s post-hoc test for multi-group comparisons. *p < 0.05 compared with control group, #p < 0.05 compared with model group, respectively Liensinine administration for 4 weeks regulates METTL3/14-mediated m6A methylation pathway in the pancreas of T2DM mice. (A, B) The expression of METTL3, METTL14, and PDX1 was analyzed using Western blot. (C)Relative mRNA expression levels of PDX1 and METTL3/14. Data are expressed as mean ± SEM (n = 3), one-way ANOVA followed by Tukey’s post-hoc test for multi-group comparisons. *p < 0.05 compared with control group, #p < 0.05 compared with model group, respectively Liensinine remodels gut microbiota composition in T2DM mice To investigate the impact of liensinine on gut microbiota composition in T2DM mice, 16 S rRNA gene sequencing was performed. The analysis revealed significant alterations in microbial community structure at both phylum and genus levels. At the phylum level (Fig. 4A), compared to the T2DM model group, liensinine treatment markedly increased the abundance of Bacteroidota, while significantly decreasing the relative abundances of Actinobacteriota and Firmicutes. At the genus level (Fig. 4B), liensinine intervention led to a significant increase in the relative abundances of Akkermansiaand norank_f_Muribaculaceae, which are generally associated with beneficial metabolic effects. Conversely, the abundance of Lactobacilluswas significantly reduced. These genus-level changes indicate a targeted regulation of specific microbial populations by liensinine. Besides this, analysis of β-diversity based on the Kruskal-Wallis H test also showed a clear separation between the model and liensinine group. Results from weighted nonmetric multidimensional scaling (NMDS) analysis at the phylum level indicated that the clusters of the liensinine group were nearly distinct from those of the T2DM group (Fig. 4C, D). Moreover, Principal coordinates analysis (PCoA) using Bray-Curtis distance metrics (Fig. 4E) similarly showed a clear separation between the model and liensinine groups, reinforcing the observation of distinct microbial community structures. The microbial dysbiosis index (MDI), an indicator of microbial community imbalance, was significantly higher in T2DM mice compared to those treated with liensinine (Fig. 4F), suggesting that liensinine intervention ameliorates microbial imbalance. A Venn diagram (Fig. 4G) illustrated the similarity and uniqueness in gut microbiota populations among different treatment groups, providing additional insights into community composition. Collectively, these findings demonstrate that liensinine effectively reshapes the gut microbiota in T2DM mice by increasing beneficial microbial populations (Bacteroidota, Akkermansia, norank_f_Muribaculaceae), reducing potentially detrimental ones (Actinobacteriota, Firmicutes, Lactobacillus), and improving overall microbial community structure and diversity. The significant separation in β-diversity metrics and reduced MDI further support the conclusion that liensinine maintains bacterial richness and diversity while effectively remodeling the gut microbiota in T2DM mice. Fig. 4Effects of 4-week liensinine administration on the gut microbiota in T2DM mice. (A) Change of gut microbiota at the phylum level. (B) Change of gut microbiota at the genus level. (C, D) Nonmetric Multidimensional Scaling (NMDS) plots (stress value < 0.2, validating reliable representation of group differences) based on Bray-Curtis dissimilarity matrices, and Kruskal-Wallis H Test applied to β-diversity metrics to identify statistically significant differences in community composition across groups. (E) Principal Coordinates Analysis (PCoA) plots generated from Bray-Curtis distance matrices. (F) Violin diagram displaying the microbial dysbiosis index (MDI) in different groups. P-values for comparisons between two groups were obtained via the Wilcox test. (G) ASV/OTU analysis. Control(c, n = 5), chow-fed mice group; Negative control(nc, n = 5), chow-fed mice group administered with liensinine; T2DM(t, n = 8), model group; T2DM + Lien(l, n = 7), model group administered with liensinine Effects of 4-week liensinine administration on the gut microbiota in T2DM mice. (A) Change of gut microbiota at the phylum level. (B) Change of gut microbiota at the genus level. (C, D) Nonmetric Multidimensional Scaling (NMDS) plots (stress value < 0.2, validating reliable representation of group differences) based on Bray-Curtis dissimilarity matrices, and Kruskal-Wallis H Test applied to β-diversity metrics to identify statistically significant differences in community composition across groups. (E) Principal Coordinates Analysis (PCoA) plots generated from Bray-Curtis distance matrices. (F) Violin diagram displaying the microbial dysbiosis index (MDI) in different groups. P-values for comparisons between two groups were obtained via the Wilcox test. (G) ASV/OTU analysis. Control(c, n = 5), chow-fed mice group; Negative control(nc, n = 5), chow-fed mice group administered with liensinine; T2DM(t, n = 8), model group; T2DM + Lien(l, n = 7), model group administered with liensinine Liensinine elevates short chain fatty acid levels in T2DM mice SCFAs play a pivotal role in maintaining intestinal microecological balance. In this study, we quantified SCFA levels to evaluate the impact of liensinine treatment on SCFA production in T2DM mice. Our results demonstrated significant alterations in SCFA profiles following liensinine administration (Fig. 5C). Specifically, absolute quantification of individual SCFAs revealed marked elevations in isohexanoic acid, acetic acid, and propanoic acid levels in T2DM mice treated with liensinine compared to untreated controls (Fig. 5A). A comprehensive heatmap integrating SCFA data across all experimental groups further illustrated these differential patterns (Fig. 5B), providing an intuitive representation of the SCFA profile changes induced by liensinine. To precisely evaluate intergroup differences in SCFA levels, we employed univariate analysis. As shown in Fig. 5D, the control and negative control (NControl) groups exhibited significantly higher levels of acetic acid, propanoic acid, and butanoic acid compared to both the T2DM model group and the liensinine-treated group (Lien). Notably, within the treatment groups, the liensinine-treated T2DM mice (Lien) demonstrated significantly elevated propanoic acid levels compared to the untreated T2DM group. Collectively, these findings demonstrate that liensinine treatment potently stimulates the production of specific SCFAs-particularly acetic acid, propanoic acid, isohexanoic acid, and to a lesser extent butanoic acid-in the fecal microbiota of T2DM mice. The significant elevation of propanoic acid in the liensinine group compared to untreated diabetics, along with the broader SCFA profile modifications, suggests that liensinine enhances intestinal microbial fermentation activity, leading to increased SCFA generation. These SCFA elevations likely contribute to the observed improvements in gut microbiota composition and metabolic parameters through their known anti-inflammatory and metabolic regulatory effects. Fig. 5Liensinine administration for 4 weeks modulates SCFAs profiles in T2DM mice. (A, B) Heat maps used to visualize SCFA levels across experimental groups; (C, D) Detailed quantitative analysis of individual SCFA species concentrations within each treatment group. (Control(c, n = 5), normal mice group; Negative control(nc, n = 5), normal mice group administered with liensinine; T2DM(t, n = 8), model group; T2DM + Lien(l, n = 7), model group administered with liensinine. Groups sharing the same letter exhibit no significant difference; different letters indicate significant differences. absence of letters denotes no significant difference Liensinine administration for 4 weeks modulates SCFAs profiles in T2DM mice. (A, B) Heat maps used to visualize SCFA levels across experimental groups; (C, D) Detailed quantitative analysis of individual SCFA species concentrations within each treatment group. (Control(c, n = 5), normal mice group; Negative control(nc, n = 5), normal mice group administered with liensinine; T2DM(t, n = 8), model group; T2DM + Lien(l, n = 7), model group administered with liensinine. Groups sharing the same letter exhibit no significant difference; different letters indicate significant differences. absence of letters denotes no significant difference Discussion Our study demonstrates that liensinine effectively restores key metabolic parameters in STZ-induced T2DM mice. The FBG showed that liensinine had a favorable effect on reducing blood glucose levels. GTT and blood lipids were also improved after liensinine treatment. Additionally, by 16 S rRNA sequencing analysis, we found that community richness and diversity analysis in the liensinine group were increased. Collectively, these findings indicate that liensinine exerts therapeutic effects in T2DM by lowering blood glucose, enhancing insulin sensitivity, and resolving lipid abnormalities—with gut microbiota modulation emerging as a critical underlying mechanism of its action. In type 2 diabetes mellitus (T2DM), despite the commonly observed hyperinsulinemia (elevated plasma insulin levels), the pancreatic β-cell mass is paradoxically reduced [20]. This discrepancy underscores the critical role of β-cell mass in maintaining glucose homeostasis. Our in vivo investigations in T2DM mice confirmed these pathological alterations, demonstrating significant reductions in islet mass, impaired islet cell proliferation, and aberrant remodeling of both α- and β-cells. Remarkably, liensinine administration in T2DM mice induced comprehensive improvements in islet architecture. Our results showed that liensinine not only restored normal islet size but also increased the masses of both α- and β-cells. These structural recoveries were accompanied by a significant enhancement in islet cell proliferation. These findings suggest that liensinine promotes β-cell regeneration, thereby reconstructing the normal islet cellular composition. The observed islet structural improvements correlated strongly with increased β-cell numbers, implicating enhanced cell proliferation as a central mechanism underlying liensinine’s islet-remodeling effects. By expanding the β-cell population, liensinine effectively preserves both the quantity and functional integrity of these insulin-producing cells. This proliferative action appears to be a pivotal strategy through which liensinine maintains β-cell mass and function in the diabetic state. In T2DM pathology, islets typically exhibit elevated α-cell glucagon secretion and reduced β-cell insulin production [21]. Consistent with these reports, our dual-immunofluorescence labeling analyses confirmed these hormonal imbalances in diabetic islets. Strikingly, liensinine treatment normalized this dysregulation, reducing excessive glucagon levels while simultaneously restoring appropriate insulin expression. This hormone-balancing effect further contributes to the overall improvement in islet function mediated by liensinine. The structural improvements in pancreatic islets observed following liensinine treatment were paralleled by significant elevations in the expression levels of METTL3/14 and PDX-1. These molecular changes are of particular interest given their established roles in pancreatic β-cell biology. In the islets of T2DM patients, METTL3/14 levels are reported to be reduced; importantly, METTL3/14 has been closely associated with the maintenance of β-cell function [19, 22]. As key components of the m6A methylation machinery, METTL3 and METTL14 are likely involved in regulating the post-translational modification of RNA molecules that are critical for β-cell homeostasis. The upregulation of METTL3/14 by liensinine suggests a potential mechanism through which this compound may enhance β-cell function via epigenetic regulation. PDX-1 is a pivotal transcription factor that plays an essential role throughout all stages of pancreatic development. It is particularly crucial for β-cell differentiation, proliferation, survival, maturation, and the maintenance of normal β-cell function [23]. By governing the expression of genes involved in these processes, PDX-1 serves as a master regulator of β-cell identity and functionality. Our experimental findings indicate that liensinine has a beneficial effect on the restoration of METTL3/14 and PDX-1 signaling pathways. The elevated expression levels of these two key molecules in the liensinine-treated group were comparable to those in the matched T2DM group, suggesting that liensinine can effectively reverse the abnormal expression patterns associated with T2DM. This restoration of METTL3/14 and PDX-1 signaling is likely to contribute to the improved islet architecture, enhanced β-cell mass, and better-regulated glucose metabolism observed in the liensinine-treated T2DM mice. Accumulating evidence underscores the critical importance of gut microbiota modulation in T2DM management [24]. The intestinal microbial community represents a key environmental factor influencing metabolic homeostasis, with growing recognition of its role in disease pathogenesis and therapeutic response. Previous studies have demonstrated liensinine’s beneficial effects on intestinal function [25, 26]. Our present results showed that the gut microbiota of T2DM mice deteriorated, including a reduction in beta diversity, However, liensinine reversed this trend. Using PCoA analysis we found that the liensinine group was significantly separated from the other groups, indicating that the gut microbiota composition was altered after the oral administration of liensinine. Our results showed that the T2DM model group had a significant reduction in beneficial bacteria (Bacteroidetes) and a concurrent increase in pathogenic bacteria (Firmicutes) compared to the control group. This Bacteroidetes/Firmicutes ratio imbalance is a well-documented hallmark of metabolic disorders, including T2DM. Notably, liensinine intervention reversed these pathological changes, significantly elevating Bacteroidetes abundance while reducing Firmicutes levels. These shifts align with previous studies linking such microbial adjustments to improved glucose tolerance [27], suggesting that liensinine may ameliorate T2DM through restoring a healthier gut microbial equilibrium. At the genus level, further distinctions emerged between the T2DM and liensinine-treated groups. The liensinine group displayed a significantly higher relative abundance of Akkermansia (a mucin-degrading commensal associated with enhanced gut barrier function [28]) and norank_f_Muribaculaceae (a predominant butyrate-producing consortium in the murine gut [29]) compared to the T2DM group. Conversely, Lactobacillus—a genus often linked to HFD-induced microbiota shifts—was markedly enriched in the T2DM group; this enrichment may reflect the progressive metabolic deterioration induced by the HFD in diabetic mice, as previously reported [30, 31]. Intestinal microbiota’s roles, notably immune regulation, nutritional support of the colonic epithelium, and barrier function maintenance, are intricately linked to SCFAs [32]. Analysis of fecal SCFA levels revealed that the T2DM model group exhibited significant reductions in acetic acid, propanoic acid, and butanoic acid compared to the control group, consistent with the known impairment of SCFA-producing consortia in T2DM. These SCFAs are critical for regulating gut barrier integrity and energy metabolism [33]. Liensinine treatment, however, reversed this SCFA deficit. Post-intervention, the T2DM + liensinine group showed significantly elevated levels of acetic acid and propanoic acid (p < 0.05) compared to the untreated T2DM group, suggesting that liensinine may restore SCFA biosynthesis by promoting the growth of SCFA-producing microbes (e.g., Akkermansia, norank_f_Muribaculaceae). Butanoic acid levels showed a trend toward an increase, further supporting the hypothesis that liensinine rescues disrupted microbial metabolic functions. Correlation analysis revealed a positive association between the abundance of norank_f_Muribaculaceae, Akkermansia, and the hypoglycemic effect of liensinine, as well as with elevated SCFA production. These findings provide novel evidence that liensinine’s hypoglycemic action is mediated, at least in part, through gut microbiota modulation. By enriching SCFA-producing taxa and restoring microbial-derived SCFA levels, liensinine likely enhances gut barrier function, reduces systemic inflammation, and improves metabolic signaling—ultimately contributing to its anti-diabetic effects. This study represents the first systematic investigation into the gut microbiota-mediated mechanisms of liensinine’s hypoglycemic activity. These insights position liensinine as a promising multi-target therapeutic agent that acts synergistically on both host metabolic pathways and the gut microbial ecosystem. The current study has several limitations that need to be addressed in subsequent research. Notably, it only establishes correlational relationships between liensinine treatment and increased expressions of METTL3/14 and PDX1, as well as alterations in the gut microbiota, without verifying direct causal links. Additionally, the study lacks in-depth analysis of functional metabolites of the gut microbiota and their associated metabolic pathways, which hinders the precise elucidation of the underlying mechanisms connecting gut microbiota changes to the biological effects of liensinine. To address these limitations, future research will focus on multiple directions: validating causal relationships through METTL3/14 knockdown, pathway inhibition, gut microbiota depletion, and fecal microbiota transplantation experiments; combining metabolomics to identify differential microbial metabolites and analyze key signaling pathways involved in the microbiota-metabolite-host interaction, thereby laying the foundation for its clinical translation. Collectively, our comprehensive investigations demonstrate that liensinine exerts robust protective effects against STZ-induced β-cell dysfunction in T2DM mice through a multifaceted mechanism. The compound upregulates the METTL3/14-mediated m6A methylation pathway and enhances PDX-1 signaling—both critical regulators of β-cell survival, proliferation, and maturation, and effectively restores the disordered gut microbiota as well as SCFA in T2DM mice. While our study elucidates the pivotal roles of METTL3/14, PDX-1, and gut microbiota in liensinine’s hypoglycemic action, the precise mechanisms underlying these interactions remain incompletely defined. Furthermore, research needs to be conducted into liensinine’s influence on m6A to elucidate the role gut microbiota plays during this process.